Steward Partners Investment Advisory LLC Buys 332 Shares of Natera, Inc. (NASDAQ:NTRA)

Steward Partners Investment Advisory LLC boosted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 1,328.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 357 shares of the medical research company’s stock after purchasing an additional 332 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Natera were worth $57,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in NTRA. Blue Trust Inc. boosted its position in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc boosted its position in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the period. Principal Securities Inc. boosted its position in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the period. True Wealth Design LLC bought a new stake in Natera during the third quarter worth approximately $57,000. Finally, Global Retirement Partners LLC boosted its position in Natera by 55.0% during the fourth quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company’s stock worth $69,000 after purchasing an additional 154 shares during the period. Institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the transaction, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 24,861 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,101,319.17. Following the completion of the sale, the insider now owns 140,684 shares of the company’s stock, valued at approximately $23,208,639.48. This trade represents a 15.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 298,946 shares of company stock valued at $47,803,462. 7.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on NTRA. Morgan Stanley upped their target price on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Robert W. Baird increased their price objective on Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Piper Sandler increased their price objective on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. JPMorgan Chase & Co. increased their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, BTIG Research reissued a “buy” rating on shares of Natera in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Natera Stock Down 2.0 %

Shares of NTRA stock opened at $146.28 on Wednesday. The stock has a market cap of $19.78 billion, a P/E ratio of -83.11 and a beta of 1.80. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The stock has a fifty day moving average price of $162.76 and a 200 day moving average price of $149.26. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.